A prospective cohort study of prognosis for newly diagnosed epilepsy in China

Yanfang Zhang, Nian Yu, Lingying Su, Qing Di*

Address: Department of Neurology, Nanjing Brain Hospital affiliated to Nanjing Medical University, 264 Guangzhou Road, Nanjing, Jiangsu Province, China

Email: Yanfang Zhang – zhangyf-88@163.com; Nian Yu – yn_doc@yahoo.cn; Lingying Su – susan.westlife@126.com; Qing Di – diqing@medmail.com.cn

*Corresponding author:

Qing Di, M.D.,

Department of Neurology,

Nanjing Brain Hospital affiliated to Nanjing Medical University,

264 Guangzhou Road, Nanjing 210029, Jiangsu Province, China

Tel: +86-2582296373; Fax: +86-2583712308;

E-mail: diqing@medmail.com.cn
Abstract

**Background:** Limited data are available on the outcome of antiepileptic drug treatment response in patients of Chinese Han ethnicity with newly diagnosed epilepsy. We sought to explore the prognosis with antiepileptic drug treatment and to identify the predictors of poor drug control of seizures in these patients.

**Methods:** For at least 2 years, we prospectively followed up a cohort of patients with newly diagnosed epilepsy and analyzed the response to each antiepileptic drug. The patients were divided into two groups (poor and good control) and compared for clinical characteristics.

**Results:** A total of 180 patients were included. Early remission was reached in 125 (69.44%) patients, 19 (10.56%) patients entered late remission, while 36 (20%) patients failed to achieve remission. The response rates of the first throughout the fourth treatment regimens were 60.0%, 16.1%, 2.8%, and 0.6%, respectively. Multiple seizure types and changes in seizure type during treatment were significantly ($p = 0.013$ and $0.047$, respectively) associated with a poor control.

**Conclusions:** The prognosis of the majority of patients with newly diagnosed epilepsy is good and the clinical pattern of epilepsy during treatment is complex. The chances of seizure control declines with each subsequent treatment regimen. The prognosis for patients with multiple seizure types and seizure type changes during treatment is unfavorable.

**Keywords:** Antiepileptic drugs, Clinical pattern, Drug-resistant epilepsy, Prognosis, Risk factors
**Background**

Epilepsy is one of the most common neurological conditions. Seventy million people have epilepsy, with the incidence of 34 – 76 of newly diagnosed cases per 100,000 [1]. While the majority of patients with epilepsy respond well to one antiepileptic drug (AED), nearly up to one third of patients respond poorly to antiepileptic therapy with two or more AEDs, or develop drug-resistant epilepsy (DRE). Uncontrolled epilepsy and overdose of AEDs are associated with adverse effects, such as cognitive deterioration, psychosocial dysfunction, and increased morbidity and mortality [2, 3]. Therefore, early identification of patients who are at high risk of developing DRE is crucial.

While the risk factors influencing the prognosis of epilepsy have begun to be appreciated [4-7], limited data are available on the clinical patterns of treatment response in newly diagnosed epilepsy. It is important to understand the different clinical patterns of response to AED treatment, ideally by following the outcomes once the treatment has been initiated. However, some current studies were limited by selection bias toward patients with drug-resistant epilepsy who had already failed at least two drug regimens [8, 9]. Further, epilepsy has heterogeneous etiology and outcomes. The disease patterns in individual patients may be genetically determined and, thus, may vary among patients from different ethnic backgrounds. Currently, a large number of epileptic individuals (estimated over six million sufferers) live in China [10], but there is no data in this population, necessitating studies on this field.

In the present study, we prospectively followed up a cohort of patients of Chinese Han ethnicity...
with newly diagnosed epilepsy to explore the prognosis with antiepileptic drug treatment and to identify the predictors of poor drug control of seizures in these patients.
Methods

Patients

In 2005, the International League against Epilepsy (ILAE) re-defined epilepsy as a disorder of
the brain characterized by an enduring predisposition to generate epileptic seizures and by the
neurobiologic, cognitive, psychological, and social consequences of this condition. The
definition of epilepsy requires the occurrence of at least one epileptic seizure [11]. In our study,
patients who had never previously received treatment with AED and who met the new definition
of epilepsy were recruited from the Neurology Clinic of Nanjing Brain Hospital between January
2000 and June 2010. The patients were prospectively followed up until the end of June 2012, i.e.,
for at least two years. Informed consent was obtained from each participant. The study was
approved by the Nanjing Brain Hospital affiliated to Nanjing Medical University Ethics
Committee.

During the first visit, we collected demographic and clinical information from patients and their
relatives using a structured questionnaire developed in-house, and performed general physical
and neurologic examinations. Electroencephalography (EEG) was performed in patients to
facilitate classification of the epilepsy, including video EEG monitoring within 24 hours and
standard stimulation procedures (photic stimulation and hyperventilation). Magnetic resonance
imaging (MRI) of the brain was performed using a high resolution 3.0 T. All MRI scans were
conducted by a specialized neuroradiologist using standard MR protocols to screen for
underlying structural abnormalities that might have caused the epilepsy. Patients with serious
systemic illnesses or seizures provoked by external factors, e.g., alcohol withdrawal, were excluded at the time of analysis.

Possible determinants were obtained prior to diagnosis and initiation of the treatment and included patients’ gender, age at the seizure onset, duration of epilepsy, seizure frequency, presence of seizures during sleep, seizure type, changes in seizure type during treatment, etiology (i.e., genetic, structural/metabolic such as head trauma, tumor, stroke, infection), family history of epilepsy, febrile seizures, history of brain injury, early mental retardation, and brain MRI and EEG findings. For either generalized onset epilepsies or focal onset epilepsies, seizures would be presented in different forms in clinical phenomenology. Multiple seizure types may coexist and the type may change during different periods in some epilepsy syndromes. So, the two factors were used to predict the outcome of epilepsy in our study. Seizure frequency was defined as the mean monthly seizure frequency within 1 year before treatment. A positive family history was defined as the presence of epilepsy in first-degree relatives (i.e., parents, siblings, and children).

**Definitions**

According to the ILAE classification of epileptic seizures [12], seizure types were categorized into generalized (tonic, clonic, or tonic–clonic) or partial (simple or complex partial). The epilepsy syndrome was classified as genetic, structural/metabolic, unknown cause, using the ILAE classification criteria of epilepsies and epileptic syndromes [13].

Outcomes were obtained from personal interviews. Remission was defined as an achievement of at least one year free of seizures, and categorized into early and late remissions. Early remission
was achieved within first year of treatment initiation, as opposed to late remission, which was achieved after more than first year of treatment. Terminal remission was regarded as remission achieved at the end of follow-up. Relapse described the occurrence of repeated seizures after remission achieved. According to the definition proposed by the ILAE [14], DRE was defined as the failure of two well-tolerated, and appropriately chosen and used AED schedules, whether as monotherapies or in combination, to achieve a sustained seizure freedom for either one year or for a period equal to three times of the pre-intervention inter-seizure time, whichever was longer.

**Treatment**

Patients were prescribed AEDs according to the seizure type, their profiles (i.e., sex, age) and drug characteristics. Monotherapy was tried initially in all patients. AEDs were increased to the maximum tolerated doses. Patients who continued to experience seizures despite at high doses of AED were designated as treatment failures because of lack of efficacy. Those developing idiosyncratic reactions or experiencing intolerable side effects at low AED doses were deemed to have failed treatment because of adverse effects. If the treatment failed, patients were prescribed another drug. Patients, whose epilepsy was difficult to control even with two single drugs, received treatment with combined drugs. Compliance with the treatment regimen was monitored at the clinic. Patients who did not comply with the treatment regimen were excluded from the study.

**Follow-up and outcome**

Patients were evaluated at 4 weeks after the treatment started and then at 3-month intervals
thereafter. At each follow-up visit, seizure frequency, drug doses, response to drug therapy and compliance were routinely recorded and adjusted, as dictated by clinical circumstances. The follow-up data were collected on a data record sheet specially developed for the purpose of this study.

The final evaluation of seizure control was performed after a minimum of 2 years of follow-up. For comparison, we divided patients into two groups. Patients who met the definition of DRE were considered to have a poor prognosis. The remaining patients were labeled as having a good prognosis.

**Statistical analysis**

All analyses were performed with SPSS 13.0 software (IBM, Chicago, USA). The two-tailed chi-square or Fisher’s exact tests were used for comparison of categorical data, while the Student’s *t* test or the Mann–Whitney test were used for comparison of continuous data. Logistic regression was used to investigate covariates of interest, first individually in univariate models and then together in a multivariate model. The odds ratio (OR) and 95% confidence interval (CI) were calculated. The two-tailed *p* value of < 0.05 was considered as statistically significant.
Results

Patient characteristics

A total of 212 patients were diagnosed with epilepsy and none had previously received an AED for any indication. Thirty-two patients (15.1%) were excluded from analysis because of lack of sufficient follow-up information. At the end of the follow-up period, outcomes were known for the remaining 180 (84.9%) patients. EEG was performed for each patient and 35 of them accepted video EEG monitoring. The median duration of the follow-up was 5 years (range 2 – 10 years). Among the 180 patients included in the study, 94 (52.2%) were male. The median (range) age at referral was 19 (6 – 71) years, and the median (range) age at the onset of epilepsy was 13 (1 – 65) years. A slightly higher number of patients (56.1%) had focal seizures, while the remaining patients (43.9%) presented with generalized seizures. Epilepsy was classified as genetic in 47 (26.1%), structural/metabolic in 55 (30.6%), and unknown cause in 78 (43.3%) patients.

Prognosis of patients with newly diagnosed epilepsy

In total, 144 (80%) patients remained seizure-free for at least one year. The remaining 36 (20%) patients never experienced a one year remission while continuing AED therapy (Figure 1).

Early remission

Early remission was reached in 125 (69.44%) out of 180 patients. Despite a good initial outcome, relapse occurred in 53 patients. The remaining 72 patients went into terminal remission with no relapse until the end of the follow-up period.
Late remission

Nineteen (10.56%) out of 180 patients entered late remission. One or more relapses were noted in 2 (1.11%) patients, but 17 (9.45%) patients remained in terminal remission without any relapse.

Rемitting course of epilepsy

Terminal remission uninterrupted by relapse was noted in 72 (40%) patients in the early remission group and in 17 (9.45%) patients who entered the late remission phase. Overall, 89 out of 180 (49.44%) patients reached the terminal remission without relapse indicating a remitting course of epilepsy.

Rемitting–relapsing course of epilepsy

Out of 144 (30.55%) patients who achieved a one year remission, the events of relapse occurred in 55 patients, indicating a remitting–relapsing course of epilepsy.

Worsening course of epilepsy

Terminal remission after relapse was noted in 19 of 53 (10.55%) patients following early remission. None of the 2 patients, whose late remission was followed by relapse, regained terminal remission. There were 34 out of 125 (18.89%) patients, whose early remission was followed by relapse, and 2 out of 19 (1.11%) patients, whose late remission was followed by relapse; these 36 patients never regained terminal remission, resulting in a total of 20% (36 / 180) patients with a worsening course of epilepsy.

Drug resistance
In total, 36 (20%) patients never experienced a one year remission during the AED therapy. Among them, 23 (12.78%) patients failed to achieve remission after using at least two AEDs and were thus defined as having DRE. The remaining 13 (7.22%) patients with no remission only received one AED therapy and could not yet be classified as DRE.

**Efficacy of AED therapy**

Among 180 patients with newly diagnosed epilepsy, 144 (80%) were seizure-free for at least one year of therapy. One-hundred eight (60%) patients achieved remission with the first AED, while 36 (20%) patients became seizure-free with subsequent drugs. The overall response rates for the first, second or third treatment schedules as proportions of the study population were 60.0%, 16.6% and 2.8%, respectively, with just one (0.6%) patient responding to further drug trials (Table 1).

In the remaining 72 patients who had uncontrolled seizures, 34 (47%) patients discontinued their first drug because of lack of efficacy, 30 (42%) because of intolerable adverse effects, 8 (11%) for other reasons, such as planning a pregnancy or a change of mind about drug treatment.

**Analysis of predictors related to seizure outcome**

At the end of follow-up, 23 of the 36 (12.78%) patients who never experienced remission were defined as DRE and classified into the poor outcome group; the remaining 157 (87.22%) patients were classified into the good outcome group. The patients of these two groups did not differ significantly with regards to gender distribution, age, age at the seizure onset, and etiology (Table 2).
By contrast, the duration of epilepsy was longer in the poor outcome group compared with the good outcome group ($p < 0.001$; Table 2). Further, a significantly higher proportion of patients had focal seizures in the poor outcome group ($p = 0.022$; Table 2).

Univariate logistic regression analysis of the patients in these two groups demonstrated that poor outcome was associated with focal seizures, multiple seizure types and changes in seizure type during therapy (Table 3). The multivariable logistic regression model further demonstrated that multiple seizure types (OR=3.33, 95% CI 1.29-8.60, $p = 0.013$) and changes in seizure type during treatment (OR=5.88, 95% CI 1.03-33.62, $p = 0.047$) were predictive of poor outcome (Table 4).
Discussion

To date, the clinical patterns of epilepsy remain poorly understood, although three different patterns of DRE have been proposed [15, 16]: the *de novo* continuous drug resistance, reversal of drug resistance, and progression to drug resistance. If different patterns exist, their recognition would be useful for counseling and planning interventions for patients with epilepsy.

The results of our study showed that 144 patients achieved remission during the follow-up period, and 17 out of 19 patients who entered late remission also remained in terminal remission with no relapse, suggesting that initial failure to enter remission cannot reliably indicate a long-term failure to achieve remission. In agreement with our data, Camfield et al. [17] found that 61% of 345 children responding to the first AED eventually went into remission. Further, 30 out of 72 (42%) children, who failed to respond to the first AED, later achieved remission thus suggesting that initial drug response cannot reliably predict drug resistance. Out of 125 patients entering early remission, 91 patients remained in remission at the end of the follow-up period, suggesting a remitting course. Furthermore, 27.2% of the patients who reached early remission were unable to regain remission after relapse, indicating a progressively worsening course of epilepsy. In 19 out of 180 (10.5%) patients, remission was followed by relapse and return to terminal remission, which suggested a remitting–relapsing pattern of epilepsy.

Uncontrolled epilepsy has an adverse impact on quality of life [18, 19]. Therefore, identification of the time point when drug resistance occurs may be useful to develop alternative interventions to prevent some forms of epilepsy from becoming drug resistant. We do not know when drug
resistance develops in the course of epilepsy, which may lead us to miss the optimal time for intervention [20].

There are three concurrent hypotheses about the evolution of drug resistance. The de novo theory stipulates that in most cases, drug resistance has been fully developed before the first seizure or at least before the start of AED therapy [16]. Findings by Kwan et al. [21] support this hypothesis. Further, our study shows the de novo drug resistance in 23 (12.78%) of 180 patients. Such patients are more likely to have poor response to the first AED prescribed. The second hypothesis indicates that there is progression from remission to drug resistance meaning that some patients develop DRE after initially responding well to the first AED. Supporting this, recent studies [22, 23] demonstrate a substantial proportion of epilepsy with the childhood onset that does not become drug resistant for many years after the onset. The third hypothesis is that drug resistance is reversible, i.e., it may remit and reappear during the course of epilepsy or the associated therapy. The reverse process is well known as an intermittent pattern in which periods of remission are followed by periods of uncontrolled seizures. Findings from randomized placebo-controlled add-on trials indicate that a small percentage of patients with previous drug-resistant partial epilepsy responded to the therapy and became seizure-free during trials with new AEDs [24]. This type of pattern also existed in our study. As mentioned above, 27.2% of our patients entering early remission were unable to reach remission again in the subsequent follow-up. Such patients could not be classified as DRE according to the definition proposed by the ILAE in 2009 [14]. In our opinion, this was not appropriate because their prognosis is
unfavorable. Therefore, the definition of DRE should be revised, and the observed time should be determined in additional studies.

An important characteristic of DRE is that most patients with intractable epilepsy are resistant to most or all AEDs. Current AEDs do not seem to prevent or reverse drug resistance in most patients [16]. At present, there are nearly 20 AEDs available to clinicians. The number of AEDs that needs to have failed in order to define DRE in a given patient has been debated in the literature [6, 7, 25, 26]. The consensus regarding the number of AED failures seems to be 2 or 3. Kwan et al. [21] found that there was a clear negative association between the number of AED regimens tried and the chances of achieving substantial remission. In their study, the respective chances of achieving remission for one year with the first, second and third AED attempts were 47%, 13% and 1%. The findings of Mohanraj et al. [27] were similar with the results of the aforementioned studies. Our results showed that overall rates of achieving a one year remission with the first, second, third and fourth AED trials were 60.0%, 16.6%, 2.8% and 0.6%, respectively. None of the patients who had experienced failure with four AED regimens became seizure-free.

Due to different study designs and the lack of a standard definition of pharmaco-resistance in the literature, the reported incidence of DRE varies from 7% to 36.7% [21, 28-30]. To the best of our knowledge, there are no data on the proportion of newly diagnosed epilepsy in the Chinese population. In our study, the incidence of DRE was approximately 13%.

It is widely recognized that early identification of patients who are at high risk of developing
DRE is important. A number of studies were published about the predictive factors for DRE such as the age of seizure onset, frequent seizures before treatment, seizure type, early mental retardation, brain imaging and EEG abnormalities [5-7, 21, 28, 29, 31-35]. The two most prominent risk factors of poor outcome identified in the present study were multiple seizure types and change in seizure type during treatment.

**Conclusions**

An array of diverse dynamic changes occurs during the course of epilepsy. Our results show that the prognosis of the majority of patients with newly diagnosed epilepsy is good. The chances of seizure control will decline with subsequent treatment regimens after the failure of the first AED treatment. Multiple seizure types and change in seizure type during treatment will predict the poor control of seizures. Patients with these risk factors should receive formal antiepileptic treatment or alternative treatments such as surgery. However, further studies with large sample size, multi-center and long-term follow-up are required to verify our observations.
Abbreviations

AED, Antiepileptic drug; DRE, Drug-resistant epilepsy; ILAE, International League against Epilepsy; EEG, Electroencephalography; MRI, Magnetic resonance imaging; OR, odds ratio; CI, confidence interval

Competing interests

The authors have no competing interests to report.

Authors’ contributions

YFZ was the principal investigator of the main research project was primarily responsible for the conduct of the study. She developed and managed the study database and drafted the manuscript. NY and LYS were the project coordinators and participated in formulating research questions, checking data for quality control. NY performed the statistical analysis. LYS contributed to image treatment and manuscript revision. QD conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors' information

Department of Neurology, Nanjing Brain Hospital affiliated to Nanjing Medical University, 264 Guangzhou Road, Nanjing, Jiangsu Province, China
Acknowledgments and funding

The research was supported by grants from the Health Department Preventive Medicine Scientific Research Foundation (Y201034) of Jiangsu Province, China. We thank Dr. Donghua Lou from the Department of Epidemiology and Statistics, Nanjing Medical University, for help with data processing and analysis.
References


Spencer SS: **How long does it take for partial epilepsy to become intractable?**
*Neurology* 2003, **60**:186-190.


28. Sillanpaa M, Schmidt D: **Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy.** *Brain* 2009, **132**:989-998.


Figure Legends

Figure 1. Outcomes for patients with newly diagnosed epilepsy.

The treatment outcomes of patients were divided into three groups: early remission (seizure-free disease achieved for at least one year within the first year of starting the therapy), late remission (seizure-free disease achieved for at least one year after more than 1 year of therapy), and no remission ever (never achieved at least one year of seizure-free disease during the follow-up period).
Additional files provided with this submission:

Additional file 1: table 1.doc, 31K
http://www.biomedcentral.com/imedia/1721845140904197/supp1.doc
Additional file 2: table 2.doc, 33K
http://www.biomedcentral.com/imedia/2094147338904257/supp2.doc
Additional file 3: table 3.doc, 45K
http://www.biomedcentral.com/imedia/8778633079042606/supp3.doc
Additional file 4: table 4.doc, 30K
http://www.biomedcentral.com/imedia/3811428109042617/supp4.doc